Therapeutic antibodies Flashcards
Alemtuzumab target
CD52
Alemtuzumab clincal uses
CLL, MS
Bevacizumab target
VEGF
Bevacizumab clinical uses
Colorectal cancer, renal cell carcinoma, non-small cell lung cancer
Cetuximab target
EGFR
Cetuximab clincal uses
Stage IV colorectal cancer, head and neck cancer
Rituximab target
CD20
Rituximab clinical indications
B-cell non-Hodgkin lymphoma, CLL, rheumatoid arthritis, Idiopathic thrombocytopenic purpura (ITP)
Trastuzumab target
HER2/neu
Trastuzumab clinical uses
Breast cancer, gastric cancer
Soluble TNF-alpha drugs
Adalimumab, certolizumab, golimumab, infliximab
Adalimumab, certolizumab, golimumab, infliximab target
Soluble TNF-alpha
Adalimumab, certolizumab, golimumab, infliximab clinical uses
IBD, Rheumatoid arthritis, Ankylosing spondylitis, Psoriasis
TNF-alpha decoy that is not a monoclonal antibody
Etanercept
Daclizumab target
CD25 (part of IL-2 receptor)
Daclizumab clinical use
Relapsing multiple sclerosis
Eculizumab target
C5 complement protein
Eculizumab clinical uses
Paroxysmal nocturnal hemoglobinuria
Natalizumab target
Alpha-4 integrin
Natalizumab clinical uses
Multiple sclerosis, Crohn disease
Risk with natalizumab
WBC adhesion, risk of PML in patient with JC virus
Ustekinumab target
IL-12/IL-23
Ustekinumab clincal uses
Psoriasis, psoriatic arthritis
Abciximab target
Platelet glycoproteins IIb/IIIa